54 Matching Annotations
  1. Last 7 days
  2. www.bmj.com www.bmj.com
    Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 area health authorities.
    1
    1. SIYANYE 21 Apr 2021

      PHLS. (1982). Efficacy of pertussis vaccination in England. Report from the PHLS Epidemiological Research Laboratory and 21 area health authorities. Br Med J (Clin Res Ed), 285(6338), 357–359. https://doi.org/10.1136/bmj.285.6338.357

      lang:en is:article efficacy pertussis vaccine vaccination England safety
    Visit annotations in context

    Tags

    Annotators

    URL

    bmj.com/content/285/6338/357
  3. Apr 2021
  4. www.thelancet.com www.thelancet.com
    Impact of anti-vaccine movements on pertussis control: the untold story
    1
    1. SIYANYE 08 Apr 2021

      Gangarosa, E. J., Galazka, A. M., Wolfe, C. R., Phillips, L. M., Miller, E., Chen, R. T., & Gangarosa, R. E. (1998). Impact of anti-vaccine movements on pertussis control: The untold story. The Lancet, 351(9099), 356–361. https://doi.org/10.1016/S0140-6736(97)04334-1

      lang:en is:article anti-vaccination pertussis coverage immunization vaccine efficacy cost-effectiveness global
    Visit annotations in context

    Tags

    Annotators

    URL

    thelancet.com/journals/lancet/article/PIIS0140-6736(97)04334-1/fulltext
  5. www.theguardian.com www.theguardian.com
    If you're pinning your hopes on a Covid vaccine, here's a dose of realism | David Salisbury
    1
    1. SIYANYE 08 Apr 2021

      If you’re pinning your hopes on a Covid vaccine, here’s a dose of realism | David Salisbury. (2020, October 21). The Guardian. http://www.theguardian.com/commentisfree/2020/oct/21/covid-vaccine-immunisation-protection

      lang:en is:article COVID-19 vaccine immunization protection infection coverage UK efficacy
    Visit annotations in context

    Tags

    Annotators

    URL

    theguardian.com/commentisfree/2020/oct/21/covid-vaccine-immunisation-protection
  6. www.theguardian.com www.theguardian.com
    Pfizer vaccine has 91% efficacy for up to six months, trial shows
    1
    1. Poppy_Schaffner 03 Apr 2021

      the Guardian. ‘Pfizer Vaccine Has 91% Efficacy for up to Six Months, Trial Shows’, 1 April 2021. http://www.theguardian.com/world/2021/apr/01/pfizer-vaccine-has-91-efficacy-for-up-to-six-months-trial-shows.

      is:article lang:en COVID-19 Pfizer efficacy trial dose vaccine german BioNTech Pfizer-BioNTech symptoms disease booster placebo
    Visit annotations in context

    Tags

    Annotators

    URL

    theguardian.com/world/2021/apr/01/pfizer-vaccine-has-91-efficacy-for-up-to-six-months-trial-shows
  7. Mar 2021
  8. www.sciencemag.org www.sciencemag.org
    A rare clotting disorder may cloud the world’s hopes for AstraZeneca’s COVID-19 vaccine
    1
    1. forbriger 31 Mar 2021

      Kupferschmidt, K., VogelMar. 27, G., 2021, & Am, 10:20. (2021, March 27). A rare clotting disorder may cloud the world’s hopes for AstraZeneca’s COVID-19 vaccine. Science | AAAS. https://www.sciencemag.org/news/2021/03/rare-clotting-disorder-may-cloud-worlds-hopes-astrazenecas-covid-19-vaccine

      is:webpage lang:en COVID-19 clotting disorder AstraZeneca vaccine US efficacy safety stroke Europe symptom death Eurpean Medicine Agency EMA Germany Heparin heparin-induced thrombocytopenia HIT
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencemag.org/news/2021/03/rare-clotting-disorder-may-cloud-worlds-hopes-astrazenecas-covid-19-vaccine
  9. www.thelancet.com www.thelancet.com
    Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
    1
    1. forbriger 31 Mar 2021

      Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E. A., Collins, A. M., Cox, T., Darton, T. C., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K. J., Flaxman, A. L., … Pollard, A. J. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(21)00628-0

      https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext

      is:article lang:en COVID-19 efficacy vaccine variant 202012/01 B.1.1.7 ChAdOx1 nCov-19 AZD1222 analysis cause UK MenACWY symptom NAAT nucleic acid amplification antibody model exploratory
    Visit annotations in context

    Tags

    Annotators

    URL

    thelancet.com/journals/lancet/article/PIIS0140-6736(21)00628-0/fulltext
  10. blogs.bmj.com blogs.bmj.com
    Covid-19 vaccine wars: developing the AstraZeneca vaccine was a triumph, but then things went wrong - The BMJ
    1
    1. jasminehollingworth 29 Mar 2021

      Covid-19 vaccine wars: Developing the AstraZeneca vaccine was a triumph, but then things went wrong. (2021, March 26). The BMJ. https://blogs.bmj.com/bmj/2021/03/26/vaccine-wars-developing-the-astrazeneca-vaccine-was-a-triumph-but-then-things-went-wrong/

      lang:en is:blog COVID-19 vaccine vaccination AstraZeneca UK news headline trial efficacy problem communication effective
    Visit annotations in context

    Tags

    Annotators

    URL

    blogs.bmj.com/bmj/2021/03/26/vaccine-wars-developing-the-astrazeneca-vaccine-was-a-triumph-but-then-things-went-wrong/
  11. www.researchsquare.com www.researchsquare.com
    Timing of COVID-19 Vaccine Approval and Endorsement by Public Figures
    1
    1. SIYANYE 19 Mar 2021

      Timing of COVID-19 Vaccine Approval and Endorsement by Public Figures. (2020). https://doi.org/10.21203/rs.3.rs-95823/v1

      lang:en is:article covid-19 vaccine public global hesitancy politics efficacy pandemic belief
    Visit annotations in context

    Tags

    Annotators

    URL

    researchsquare.com/article/rs-95823/v1
  12. www.sciencedirect.com www.sciencedirect.com
    Vaccine hesitancy and healthcare providers
    1
    1. SIYANYE 19 Mar 2021

      Paterson, P., Meurice, F., Stanberry, L. R., Glismann, S., Rosenthal, S. L., & Larson, H. J. (2016). Vaccine hesitancy and healthcare providers. Vaccine, 34(52), 6700–6706. https://doi.org/10.1016/j.vaccine.2016.10.042

      lang:en is:article vaccine hesitancy healthcare behavior attitude intervention efficacy safety
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0264410X1630977X
  13. link.springer.com link.springer.com
    Self-efficacy and HPV Vaccine Attitudes Mediate the Relationship Between Social Norms and Intentions to Receive the HPV Vaccine Among College Students
    1
    1. SIYANYE 19 Mar 2021

      Stout, M. E., Christy, S. M., Winger, J. G., Vadaparampil, S. T., & Mosher, C. E. (2020). Self-efficacy and HPV Vaccine Attitudes Mediate the Relationship Between Social Norms and Intentions to Receive the HPV Vaccine Among College Students. Journal of Community Health, 45(6), 1187–1195. https://doi.org/10.1007/s10900-020-00837-5

      lang:en is:article self-efficacy HPV vaccine attitude mediation social norm intention mechanism social support parental support intervention young adult student
    Visit annotations in context

    Tags

    Annotators

    URL

    link.springer.com/article/10.1007/s10900-020-00837-5
  14. www.tandfonline.com www.tandfonline.com
    The Missing Link in the Covid-19 Vaccine Race
    1
    1. SIYANYE 19 Mar 2021

      Zizzo, J. (2020). The Missing Link in the Covid-19 Vaccine Race. Human Vaccines & Immunotherapeutics, 0(0), 1–3. https://doi.org/10.1080/21645515.2020.1831859

      lang:en is:article Covid-19 vaccine marketing immunization campaign hesitancy COVID-19 distribution efficacy safety
    Visit annotations in context

    Tags

    Annotators

    URL

    tandfonline.com/doi/full/10.1080/21645515.2020.1831859
  15. twitter.com twitter.com
    Tweet / Twitter
    1
    1. alexandra.p 19 Mar 2021

      A Marm Kilpatrick. (2021, February 9). Vaccine efficacy in blocking infection & transmission (I think) We can now estimate the (minimum) reduction in transmission from the Moderna vaccine. Thread tl;dr Moderna vaccine blocks >90% (87-93%) of infections & 91% (89-94%) of transmission. *Critiques welcome! Https://t.co/GjQIo3v4oe [Tweet]. @DiseaseEcology. https://twitter.com/DiseaseEcology/status/1359213735424872450

      is:tweet lang:en vaccine transmission Moderna reduction AstraZeneca COVID-19 efficacy Pfizer BioNTech infection disease symptomatic asymptomatic trial viral load
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/diseaseecology/status/1359213735424872450
  16. Local file Local file
    Untitled document
    1
    1. alexandra.p 19 Mar 2021

      Smith, P. (2021). Interim recommendations for use of the AZD1222 (ChAdOx1-S (recombinant)) vaccine against COVID-19 developed by Oxford University and AstraZeneca. WHO.

      is:pdf lang:en COVID-19 vaccine Oxford AstraZeneca interim guidance WHO SAGE recommendation clinical trial efficacy interdose interval

    Tags

    Annotators

  17. www.nature.com www.nature.com
    Russia’s fast-track coronavirus vaccine draws outrage over safety
    1
    1. SIYANYE 19 Mar 2021

      Callaway, E. (2020). Russia’s fast-track coronavirus vaccine draws outrage over safety. Nature, 584(7821), 334–335. https://doi.org/10.1038/d41586-020-02386-2

      lang:en is:news Covid-19 vaccine Russia immunization safety efficacy
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/d41586-020-02386-2
  18. www.bmj.com www.bmj.com
    Delaying the second dose of covid-19 vaccines
    1
    1. Poppy_Schaffner 18 Mar 2021

      Pimenta, Dominic, Christian Yates, Christina Pagel, and Deepti Gurdasani. ‘Delaying the Second Dose of Covid-19 Vaccines’. BMJ 372 (18 March 2021): n710. https://doi.org/10.1136/bmj.n710.

      is:article lang:en COVID-19 pandemic vaccine vaccination vaccine development effectiveness protocol Pfizer-BioNTech Oxford-AstraZeneca doses efficacy age groups maximise benefits hospitalised admissions deaths delay dose guarantee older adults
    Visit annotations in context

    Tags

    Annotators

    URL

    bmj.com/content/372/bmj.n710
  19. www.thelancet.com www.thelancet.com
    What does 95% COVID-19 vaccine efficacy really mean?
    1
    1. jasminehollingworth 15 Mar 2021

      Olliaro, P. (2021). What does 95% COVID-19 vaccine efficacy really mean? The Lancet Infectious Diseases, 0(0). https://doi.org/10.1016/S1473-3099(21)00075-X

      lang:en is:article COVID-19 vaccine vaccination efficacy effectiveness symptomatic population disease disease protection misconception reduction risk exposure transmission
    Visit annotations in context

    Tags

    Annotators

    URL

    thelancet.com/journals/laninf/article/PIIS1473-3099(21)00075-X/fulltext
  20. twitter.com twitter.com
    Hilda Bastian, PhD on Twitter
    1
    1. emilybiggs 15 Mar 2021

      Hilda Bastian, PhD. (2021, February 6). Unofficial unnamed AstraZeneca insider says they are doing the interim analysis for the US trial of the Oxford vaccine. AstraZeneca spokesperson says 4-6 weeks till data release. Https://t.co/VUHgbHN02d One is wrong? Or they’ll release only when have FDA minimum follow-up? Https://t.co/LgjfX8AIti [Tweet]. @hildabast. https://twitter.com/hildabast/status/1357862227106095105

      is:twitter lang:en COVID-19 AstraZeneca vaccine vaccine trials efficacy UK USA diversity placebo Cuba variants
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/hildabast/status/1357862227106095105
  21. www.reuters.com www.reuters.com
    Exclusive: Oxford study indicates AstraZeneca effective against Brazil variant, source says
    1
    1. sophia.sterckx 15 Mar 2021

      Gaier, Rodrigo Viga. ‘Exclusive: Oxford Study Indicates AstraZeneca Effective against Brazil Variant, Source Says’. Reuters, 5 March 2021. https://www.reuters.com/article/us-health-coronavirus-brazil-variant-exc-idUSKBN2AX1NS.

      is:article lang:en Brazil Rio De Janeiro Oxford University COVID-19 vaccine AstraZeneca new variant variant efficacy of vaccine P1 south african variant
    Visit annotations in context

    Tags

    Annotators

    URL

    reuters.com/article/us-health-coronavirus-brazil-variant-exc-idUSKBN2AX1NS
  22. papers.ssrn.com papers.ssrn.com
    Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine
    1
    1. emilybiggs 15 Mar 2021

      Voysey, M., Costa Clemens, S. A., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B. J., Baillie, V., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Clutterbuck, E., Collins, A. M., Cutland, C., Darton, T., Dheda, K., Douglas, A. D., … Group, O. C. V. T. (2021). Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine (SSRN Scholarly Paper ID 3777268). Social Science Research Network. https://papers.ssrn.com/abstract=3777268

      lang:en COVID-19 vaccine single dose timing booster dose efficacy UK is:preprint
    Visit annotations in context

    Tags

    Annotators

    URL

    papers.ssrn.com/sol3/papers.cfm
  23. absolutelymaybe.plos.org absolutelymaybe.plos.org
    Variants, 3 New Covid Vaccines, and Contested Efficacy Claims: A Month of Seismic Shifts and Confusion - Absolutely Maybe
    1
    1. emilybiggs 15 Mar 2021

      Variants, 3 New Covid Vaccines, and Contested Efficacy Claims: A Month of Seismic Shifts and Confusion. (2021, January 31). Absolutely Maybe. https://absolutelymaybe.plos.org/2021/01/31/variants-3-new-covid-vaccines-and-contested-efficacy-claims-a-month-of-seismic-shifts-and-confusion/

      is:blog lang:en COVID-19 variants vaccine efficacy outbreaks vaccine trials evidence
    Visit annotations in context

    Tags

    Annotators

    URL

    absolutelymaybe.plos.org/2021/01/31/variants-3-new-covid-vaccines-and-contested-efficacy-claims-a-month-of-seismic-shifts-and-confusion/
  24. papers.ssrn.com papers.ssrn.com
    Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
    1
    1. emilybiggs 15 Mar 2021

      Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B. J., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E., Collins, A. M., Cox, T., Darton, T., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K., Flaxman, A., … Group, O. C. V. T. (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7) (SSRN Scholarly Paper ID 3779160). Social Science Research Network. https://doi.org/10.2139/ssrn.3779160

      is:preprint lang:en COVID-19 vaccine efficacy variant symptoms antibody
    Visit annotations in context

    Tags

    Annotators

    URL

    papers.ssrn.com/sol3/papers.cfm
  25. www.ox.ac.uk www.ox.ac.uk
    Economist Professor Sir Tony Atkinson 'pioneered the study of inequality' | University of Oxford
    1
    1. emilybiggs 15 Mar 2021

      ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults | University of Oxford. (n.d.). Retrieved February 18, 2021, from https://www.ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection-against-mild-moderate-covid-19-infection

      is:news lang:en COVID-19 vaccine variant South Africa protection vaccine trials efficacy
    Visit annotations in context

    Tags

    Annotators

    URL

    ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection-against-mild-moderate-covid-19-infection
  26. www.sciencedirect.com www.sciencedirect.com
    Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia
    1
    1. SIYANYE 11 Mar 2021

      Yufika, A., Wagner, A. L., Nawawi, Y., Wahyuniati, N., Anwar, S., Yusri, F., Haryanti, N., Wijayanti, N. P., Rizal, R., Fitriani, D., Maulida, N. F., Syahriza, M., Ikram, I., Fandoko, T. P., Syahadah, M., Asrizal, F. W., Aletta, A., Haryanto, S., Jamil, K. F., … Harapan, H. (2020). Parents’ hesitancy towards vaccination in Indonesia: A cross-sectional study in Indonesia. Vaccine, 38(11), 2592–2599. https://doi.org/10.1016/j.vaccine.2020.01.072

      lang:en is:article hesitancy vaccine vaccination barrier trial parent coverage acceptance Indonesia efficacy safety dissemination trust
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencedirect.com/science/article/pii/S0264410X20301146
  27. twitter.com twitter.com
    David Benkeser on Twitter
    1
    1. jasminehollingworth 03 Mar 2021

      David Benkeser. (2020, November 9). Another view on uncertainty associated based on Pfizer’s results. Even if you were highly skeptical about MRNA vaccines (many are [were?]) with 50% prior belief that VE ~ 0, based on an 8:86 vax:placebo case split, the posterior probability that VE > 75% is ~ 1. Https://t.co/xtBONtGHmT [Tweet]. @biosbenk. https://twitter.com/biosbenk/status/1325856366225993729

      lang:en is:twitter COVID-19 pandemic vaccine vaccination Pfizer result skeptical skepticism efficacy trust photo image graph statistics
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/biosbenk/status/1325856366225993729
  28. Feb 2021
  29. twitter.com twitter.com
    Tweet / Twitter
    1
    1. XanaButt 25 Feb 2021

      Carl T. Bergstrom. (2021, January 31). A somewhat technical thread about measuring vaccine efficacy. We’re used to the notion that certain properties of tests for disease depend on prevalence: Positive and negative predictive value do, for example, whereas sensitivity and specificity do not. [Tweet]. @CT_Bergstrom. https://twitter.com/CT_Bergstrom/status/1355762090078703621

      is:twitter lang:en COVID-19 vaccine efficacy sensitivity prevalence exposure risk placebo modeling transmission
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/reconfigbehsci/status/1356157273031266305
  30. www.nejm.org www.nejm.org
    Placebo-Controlled Trials of Covid-19 Vaccines — Why We Still Need Them | NEJM
    1
    1. XanaButt 25 Feb 2021

      Placebo-Controlled Trials of Covid-19 Vaccines—Why We Still Need Them. (2021). New England Journal of Medicine, 384(2), e2. https://doi.org/10.1056/NEJMp2033538

      is:article lang:en COVID-19 vaccine efficacy limited public health confidence information gap short-term protection worldwide WHO
    Visit annotations in context

    Tags

    Annotators

    URL

    nejm.org/doi/full/10.1056/NEJMp2033538
  31. theconversation.com theconversation.com
    Herd immunity is the end game for the pandemic, but the AstraZeneca vaccine won’t get us there
    1
    1. jasminehollingworth 24 Feb 2021

      Hyde, Z. (n.d.). Herd immunity is the end game for the pandemic, but the AstraZeneca vaccine won’t get us there. The Conversation. Retrieved 24 February 2021, from http://theconversation.com/herd-immunity-is-the-end-game-for-the-pandemic-but-the-astrazeneca-vaccine-wont-get-us-there-155115

      lang:en is:news COVID-19 pandemic Australia vaccine vaccination herd immunity immunity policy strategy dose government high risk population efficacy outbreak
    Visit annotations in context

    Tags

    Annotators

    URL

    theconversation.com/herd-immunity-is-the-end-game-for-the-pandemic-but-the-astrazeneca-vaccine-wont-get-us-there-155115
  32. hackmd.io hackmd.io
    Potential Side Effects of COVID-19 Vaccines - HackMD
    1
    1. zoe_ikeotuonye 22 Feb 2021

      Potential Side Effects of COVID-19 Vaccines. (n.d.). HackMD. Retrieved 22 February 2021, from https://hackmd.io/@scibehC19vax/sideeffects

      is:webpage COVID-19 efficacy side effect vaccine long-term allergic reaction vaccination pandemic health policy health public health
    Visit annotations in context

    Tags

    Annotators

    URL

    hackmd.io/@scibehC19vax/sideeffects
  33. hackmd.io hackmd.io
    Myths about COVID-19 vaccination - HackMD
    1
    1. Lu17Cheryl 19 Feb 2021

      “Myths about COVID-19 vaccination - HackMD.” Accessed February 19, 2021. https://hackmd.io/ovEzSQWcRp2bctQn8MYElQ#Myths-about-COVID-19-vaccination.

      is:webpage lang:en COVID-19 pandemic Coronavirus handbook vaccine misinformation myths efficacy injection vulnerability DNA mRNA elderly people fertility the AstraZenica vaccine the Oxford vaccine prevention sexual orientation European Union UK critical thinking
    Visit annotations in context

    Tags

    Annotators

    URL

    hackmd.io/ovEzSQWcRp2bctQn8MYElQ
  34. www.biorxiv.org www.biorxiv.org
    http://biorxiv.org/cgi/content/short/2021.01.18.427166
    1
    1. marta_radosevic 18 Feb 2021

      Wibmer, C. K., Ayres, F., Hermanus, T., Madzivhandila, M., Kgagudi, P., Lambson, B. E., Vermeulen, M., Berg, K. van den, Rossouw, T., Boswell, M., Ueckermann, V., Meiring, S., Gottberg, A. von, Cohen, C., Morris, L., Bhiman, J. N., & Moore, P. L. (2021). SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. BioRxiv, 2021.01.18.427166. https://doi.org/10.1101/2021.01.18.427166

      is:preprint lang:en COVID-19 South Africa SARS-CoV-2 501Y.V2 mutation reinfection efficacy vaccine research transmission strain
    Visit annotations in context

    Tags

    Annotators

    URL

    biorxiv.org/content/10.1101/2021.01.18.427166v1
  35. twitter.com twitter.com
    ReconfigBehSci on Twitter
    1
    1. NatasjaDerbyMcCabe 15 Feb 2021

      ReconfigBehSci. (2021, February 12). RT @NatureNews: The science behind how and when to give vaccines doses. Https://t.co/S75TXESOG9 [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1360489348223893505

      is:tweet lang:en COVID-19 vaccine vaccine efficacy doses logistical concerns memory cells US UK Russia Oxford Sputnik V AstraZeneca Pfizer vaccine antibody levels mixing vaccines combine vaccines 1st generation vaccines
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/SciBeh/status/1360489348223893505
  36. www.nature.com www.nature.com
    Coronapod: Is mixing COVID vaccines a good idea?
    1
    1. NatasjaDerbyMcCabe 15 Feb 2021

      Thompson, B., Baker, N., & Ledford, H. (2021). Coronapod: Is mixing COVID vaccines a good idea? Nature. https://doi.org/10.1038/d41586-021-00390-8

      is:other lang:en COVID-19 vaccine vaccine efficacy doses logistical concerns memory cells US UK Russia Oxford Sputnik V AstraZeneca Pfizer vaccine antibody levels mixing vaccines combine vaccines 1st generation vaccines
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/d41586-021-00390-8
  37. www.gov.uk www.gov.uk
    Prioritising the first COVID-19 vaccine dose: JCVI statement
    1
    1. jasminehollingworth 13 Feb 2021

      Prioritising the first COVID-19 vaccine dose: JCVI statement. (n.d.). GOV.UK. Retrieved 13 February 2021, from https://www.gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement

      lang:en is:report COVID-19 vaccine vaccination immunisation impact programme efficacy dose prioritise prioritization
    Visit annotations in context

    Tags

    Annotators

    URL

    gov.uk/government/publications/prioritising-the-first-covid-19-vaccine-dose-jcvi-statement
  38. www.scientificamerican.com www.scientificamerican.com
    The Second-Generation COVID Vaccines Are Coming
    1
    1. jasminehollingworth 11 Feb 2021

      Cormier, Z. (n.d.). The Second-Generation COVID Vaccines Are Coming. Scientific American. Retrieved 11 February 2021, from https://www.scientificamerican.com/article/the-second-generation-covid-vaccines-are-coming/

      lang:en is:news COVID-19 vaccine distribution efficacy production pandemic USA UK development transmission variant public carrier immunity
    Visit annotations in context

    Tags

    Annotators

    URL

    scientificamerican.com/article/the-second-generation-covid-vaccines-are-coming/
  39. medrxiv.org medrxiv.org
    http://medrxiv.org/cgi/content/short/2020.12.27.20248896
    1
    1. jasminehollingworth 09 Feb 2021

      Moore, S., Hill, E. M., Tildesley, M. J., Dyson, L., & Keeling, M. J. (2021). Vaccination and Non-Pharmaceutical Interventions: When can the UK relax about COVID-19? MedRxiv, 2020.12.27.20248896. https://doi.org/10.1101/2020.12.27.20248896

      lang:en is:preprint COVID-19 vaccine intervention UK efficacy illness death healthcare vaccination infection risk hospital NPI outbreak public health herd immunity protection consequence public
    Visit annotations in context

    Tags

    Annotators

    URL

    medrxiv.org/cgi/content/short/2020.12.27.20248896
  40. fullfact.org fullfact.org
    Report of 8% vaccine efficacy for elderly debunked by German government
    1
    1. jasminehollingworth 08 Feb 2021

      Report of 8% vaccine efficacy for elderly debunked by German government. (14:24:16+00:00). Full Fact. https://fullfact.org/health/german-astrazeneca-8-percent-handelsblatt/

      lang:en is:blog COVID-19 AstraZeneca vaccine efficacy eldery German Germany government effectiveness misunderstood trial participants public data immune response newspaper Oxford
    Visit annotations in context

    Tags

    Annotators

    URL

    fullfact.org/health/german-astrazeneca-8-percent-handelsblatt/
  41. www.nihr.ac.uk www.nihr.ac.uk
    Novavax COVID-19 vaccine 89.3% effective
    1
    1. marta_radosevic 01 Feb 2021

      Novavax COVID-19 vaccine 89.3% effective. (n.d.). Retrieved 1 February 2021, from https://www.nihr.ac.uk/news/novavax-covid-19-vaccine-893-effective/26720

      is:webpage lang:en NIHR Novavax COVID-19 vaccine efficacy prevention UK clinical trial USA NHS result
    Visit annotations in context

    Tags

    Annotators

    URL

    nihr.ac.uk/news/novavax-covid-19-vaccine-893-effective/26720
  42. Jan 2021
  43. www.news-medical.net www.news-medical.net
    Analysis supports phase 3 trials of Johnson & Johnson's COVID-19 vaccine
    1
    1. marta_radosevic 20 Jan 2021

      Analysis supports phase 3 trials of Johnson & Johnson’s COVID-19 vaccine. (2021, January 17). News-Medical.Net. https://www.news-medical.net/news/20210117/Analysis-supports-phase-3-trials-of-Johnson-Johnsons-COVID-19-vaccine.aspx

      is:news lang:en vaccine analysis result safety efficacy COVID-19 Johnson & Johnson clinical trial
    Visit annotations in context

    Tags

    Annotators

    URL

    news-medical.net/news/20210117/Analysis-supports-phase-3-trials-of-Johnson-Johnsons-COVID-19-vaccine.aspx
  44. www.nature.com www.nature.com
    Toward superhuman SARS-CoV-2 immunity?
    1
    1. SIYANYE 13 Jan 2021

      Burton, D. R., & Topol, E. J. (2021). Toward superhuman SARS-CoV-2 immunity? Nature Medicine, 27(1), 5–6. https://doi.org/10.1038/s41591-020-01180-x

      lang:en is:article immunity Covid-19 vaccine infection natural protection toxin virus efficacy
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/s41591-020-01180-x
  45. twitter.com twitter.com
    ReconfigBehSci on Twitter
    1
    1. SIYANYE 13 Jan 2021

      ReconfigBehSci. (2020, November 9). RT @peterbachmd: Relevant today: Ever sharp @nataliexdean on Vaccine Effectiveness vs Efficacy from many moons ago (i.e. About a month). Sh… [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1325889181097267200

      is:tweet lang:en vaccine effectiveness efficacy infection disease
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/SciBeh/status/1325889181097267200
  46. www.theatlantic.com www.theatlantic.com
    Vaccine Chaos Is Looming
    1
    1. marta_radosevic 11 Jan 2021

      Zhang, S. (2020, September 28). Vaccine Chaos Is Looming. The Atlantic. https://www.theatlantic.com/health/archive/2020/09/covid-19-most-complicated-vaccine-campaign-ever/616521/

      is:news lang:en COVID-19 vaccine clinical trial Moderna Pfizer-BioNTech logistics safety efficacy challenge approval distribution
    Visit annotations in context

    Tags

    Annotators

    URL

    theatlantic.com/health/archive/2020/09/covid-19-most-complicated-vaccine-campaign-ever/616521/
  47. www.theatlantic.com www.theatlantic.com
    The Long Haul of Vaccine Results Is Just Beginning
    1
    1. marta_radosevic 11 Jan 2021

      Zhang, S. (2020, December 1). The Long Haul of Vaccine Results Is Just Beginning. The Atlantic. https://www.theatlantic.com/health/archive/2020/12/vaccine-trials-can-still-surprise-us/617247/

      is:news lang:en COVID-19 vaccine result AstraZeneca Oxford trial data efficacy vector manufacture error
    Visit annotations in context

    Tags

    Annotators

    URL

    theatlantic.com/health/archive/2020/12/vaccine-trials-can-still-surprise-us/617247/
  48. www.theatlantic.com www.theatlantic.com
    The End of the Pandemic Is Now in Sight
    1
    1. marta_radosevic 11 Jan 2021

      Zhang, S. (2020, November 18). The End of the Pandemic Is Now in Sight. The Atlantic. https://www.theatlantic.com/health/archive/2020/11/vaccines-end-covid-19-pandemic-sight/617141/

      is:news lang:en pandemic vaccine COVID-19 science Pfizer Moderna efficacy
    Visit annotations in context

    Tags

    Annotators

    URL

    theatlantic.com/health/archive/2020/11/vaccines-end-covid-19-pandemic-sight/617141/
  49. Dec 2020
  50. www.nature.com www.nature.com
    The UK has approved a COVID vaccine — here’s what scientists now want to know
    1
    1. marta_radosevic 23 Dec 2020

      Ledford, H., Cyranoski, D., & Noorden, R. V. (2020). The UK has approved a COVID vaccine—Here’s what scientists now want to know. Nature, 588(7837), 205–206. https://doi.org/10.1038/d41586-020-03441-8

      is:news lang:en UK COVID-19 vaccine Pfizer-BioNTech research safety efficacy clinical trial front line workers health workers care home staff care home residents transmission approval
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/d41586-020-03441-8
  51. www.nature.com www.nature.com
    Oxford COVID-vaccine paper highlights lingering unknowns about results
    1
    1. ErikStuchly 10 Dec 2020

      Ledford, H. (2020). Oxford COVID-vaccine paper highlights lingering unknowns about results. Nature. https://doi.org/10.1038/d41586-020-03504-w

      is:news is:article lang:en COVID-19 research clinical trial vaccine candidate phase 3 trial immunology Oxford efficacy safety uncertainty asymptomatic infection
    Visit annotations in context

    Tags

    Annotators

    URL

    nature.com/articles/d41586-020-03504-w
  52. www.thelancet.com www.thelancet.com
    Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
    1
    1. ErikStuchly 10 Dec 2020

      Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., Angus, B., Baillie, V. L., Barnabas, S. L., Bhorat, Q. E., Bibi, S., Briner, C., Cicconi, P., Collins, A. M., Colin-Jones, R., Cutland, C. L., Darton, T. C., Dheda, K., Duncan, C. J. A., … Zuidewind, P. (2020). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)32661-1

      is:article lang:en COVID-19 vaccine candidate Brazil randomized controlled trials clinical trial UK South Africa safety efficacy analysis
    Visit annotations in context

    Tags

    Annotators

    URL

    thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext
  53. investors.modernatx.com investors.modernatx.com
    Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc.
    1
    1. marta_radosevic 01 Dec 2020

      Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study | Moderna, Inc. (n.d.). Retrieved 1 December 2020, from https://investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/

      is:webpage lang:en COVID-19 Moderna vaccine phase 3 study vaccine efficacy analysis patient safety biotechnology
    Visit annotations in context

    Tags

    Annotators

    URL

    investors.modernatx.com/news-releases/news-release-details/modernas-covid-19-vaccine-candidate-meets-its-primary-efficacy/
  54. Nov 2020
  55. www.sciencemag.org www.sciencemag.org
    ‘Just beautiful’: Another COVID-19 vaccine, from newcomer Moderna, succeeds in large-scale trial
    1
    1. marta_radosevic 18 Nov 2020

      CohenNov. 16, J., 2020, & Am, 7:00. (2020, November 16). ‘Just beautiful’: Another COVID-19 vaccine, from newcomer Moderna, succeeds in large-scale trial. Science | AAAS. https://www.sciencemag.org/news/2020/11/just-beautiful-another-covid-19-vaccine-newcomer-moderna-succeeds-large-scale-trial

      is:webpage lang:en vaccine COVID-19 trial Moderna USA distribution efficacy Pfizer BioNTech optimism health mRNA technology
    Visit annotations in context

    Tags

    Annotators

    URL

    sciencemag.org/news/2020/11/just-beautiful-another-covid-19-vaccine-newcomer-moderna-succeeds-large-scale-trial
  56. Sep 2020
  57. twitter.com twitter.com
    The Root on Twitter
    1
    1. Gaurav_Saxena 30 Sep 2020

      Natalie E. Dean en Twitter: “VACCINE EFFICACY 101: A biostatistician's primer. Ten tweets to cover:- How is vaccine efficacy calculated?- Distinguishing between infection, disease, & severe disease.- Measuring reduced infectiousness.- Vaccine efficacy vs. effectiveness!n” / Twitter. (n.d.). Twitter. Retrieved September 30, 2020, from https://twitter.com/nataliexdean/status/1310613702476017666

      COVID-19 value biostatistician primer vaccine development vaccine efficacy infection desease vaccine effectiveness infection prevention is:twitter lang:en
    Visit annotations in context

    Tags

    Annotators

    URL

    twitter.com/TheRoot/status/1140355897752981504
  58. osf.io osf.io
    Heard immunity: effective persuasion for a future COVID-19 vaccine
    1
    1. ErikStuchly 16 Sep 2020

      Duquette, N. (2020). Heard immunity: Effective persuasion for a future COVID-19 vaccine. https://doi.org/10.31235/osf.io/jwvsp

      is:preprint lang:en COVID-19 herd immunity persuasion vaccine hesitancy risk perception safety ethnicity prosocial behavior altruism efficacy strategy opinion change
    Visit annotations in context

    Tags

    Annotators

    URL

    osf.io/preprints/socarxiv/jwvsp/
  59. Aug 2020
  60. www.thelancet.com www.thelancet.com
    Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
    1
    1. ErikStuchly 28 Aug 2020

      Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., … Chen, W. (2020). Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet, 0(0). https://doi.org/10.1016/S0140-6736(20)31605-6

      is:article lang:en COVID-19 immunogenicity safety vaccine randomized controlled trial double-blind phase 2 trial candidate efficacy immune response
    Visit annotations in context

    Tags

    Annotators

    URL

    thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/fulltext
  61. www.newscientist.com www.newscientist.com
    Everything you need to know about Russia's coronavirus vaccine claims
    1
    1. ErikStuchly 18 Aug 2020

      Marshall, M. (n.d.). Everything you need to know about Russia’s coronavirus vaccine claims. New Scientist. Retrieved August 18, 2020, from https://www.newscientist.com/article/2251722-everything-you-need-to-know-about-russias-coronavirus-vaccine-claims/

      is:news lang:en COVID-19 Russia vaccine concern development immunology safety efficacy transparency strategy bad science public health spike protein
    Visit annotations in context

    Tags

    Annotators

    URL

    newscientist.com/article/2251722-everything-you-need-to-know-about-russias-coronavirus-vaccine-claims/
  62. www.nber.org www.nber.org
    Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs
    1
    1. ErikStuchly 15 Aug 2020

      Lo, A. W., Siah, K. W., & Wong, C. H. (2020). Estimating Probabilities of Success of Vaccine and Other Anti-Infective Therapeutic Development Programs (Working Paper No. 27176; Working Paper Series). National Bureau of Economic Research. https://doi.org/10.3386/w27176

      is:preprint lang:en COVID-19 probability estimation vaccine efficacy therapeutic development drug clinical trial public sector support implication success
    Visit annotations in context

    Tags

    Annotators

    URL

    nber.org/papers/w27176
  63. www.theatlantic.com www.theatlantic.com
    A Vaccine Reality Check
    1
    1. ErikStuchly 09 Aug 2020

      A Vaccine Reality Check. (n.d.). MSN. Retrieved August 9, 2020, from https://www.msn.com/en-us/news/us/a-vaccine-reality-check/ar-BB178Yaf

      is:news lang:en COVID-19 vaccine mistrust misinformation conspiracy efficacy development epidemiology cost government response strategy
    Visit annotations in context

    Tags

    Annotators

    URL

    theatlantic.com/health/archive/2020/07/covid-19-vaccine-reality-check/614566/